Search Results - juan+marugan

18 Results Sort By:
CD206 Small Molecule Modulators, Their Use and Methods for Preparation
Abstract: Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive malignancies with a 5-year survival rate of 6%. The high mortality rate caused by PDA is primarily from the lack of early diagnosis – it is often asymptomatic in early stages – and a poor response to conventional...
Published: 4/8/2024   |   Inventor(s): Udo Rudloff, Juan Marugan, Xin Hu, Raul Calvo, Noel Southall, Bolormaa Baljinnyam
Keywords(s): CD206, M1 Macrophage, M2 Macrophage, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDA, Rudloff, TAM, Tumor-Associated Macrophages
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
Autophagy Modulators For Use in Treating Cancer
Abstract: Cancer cells can upregulate autophagy – cell destruction – as a response to chemotherapy. Investigators in Dr. Melvin DePamphilis’ laboratory at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have shown that compounds identified by screening a library of compounds blocks autophagy in some cancer...
Published: 4/8/2024   |   Inventor(s): Melvin DePamphilis, Gaurav Sharma, Marc Ferrer-Alegre, Juan Marugan, Ajit Roy
Keywords(s): BRAF Mutation, Depamphilis, Eunice Kennedy Shriver National Institute of Child Health an, Inhibition of Autophagy, NICHD, WX8
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
The Use of Emetine for the Treatment of SARS-CoV-2 Infection
This technology includes the clinical use of the small compound emetine for the treatment of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues...
Published: 10/28/2024   |   Inventor(s): Mark Henderson, Juan Marugan, Andreas Dulcey Garcia, Xin Hu, Marc Ferrer-Alegre, Noel Southall
Keywords(s): Emetine, Infection, SARS-CoV-2, treatment, VLXXXX, WIXXXX, WKXXXX
Category(s): TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Research Materials
Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers
The technology includes the creation of a high-throughput assay and the identification and use of small molecules that inhibit the SIX/EYA interaction as a treatment for cancer. The Eya proteins are phosphatases that form a complex and are activated by the Six family of homeobox transcription factors. The interaction of Eya and Six mediates breast cancer...
Published: 10/28/2024   |   Inventor(s): Marc Ferrer-Alegre, Xin Hu, Juan Marugan, Lesley Mathews, Heide Ford, Melanie Blevins, Rebecca Mull, Rui Zhao
Keywords(s): cancers, Identification, Identifying, Inhibitors, INTERACTION, Listed LPM Vathyam as of 4/15/2015, Method, MOLECULE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SIX/EYA, Small, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology
Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction
This technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein...
Published: 10/28/2024   |   Inventor(s): Noel Southall, Marc Ferrer-Alegre, Daniel Jansen, Mark Henderson, Xin Hu, David Kim, Juan Marugan
Keywords(s): ADDICTION, Chemical, FOOD, Funtionally, Ghrelin, LIGAND, NCG00538279, Novel, RECEPTOR, SELECTIVE, treatment, VEXXXX, VGXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Neurology, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Research Materials
Creation and Use of Kinetin Derivatives for Treating RNA Missplicing Diseases Such as Familial Dysautonomia
This technology includes the creation and use of compounds, including kinetin derivatives, that improve mRNA splicing in a cell for the treatment of disorders associated with misspliced mRNA, including familial dysautonomia (FD). FD, the best-known and most common member of a group of congenital sensory and autonomic neuropathies, affects neuronal development...
Published: 10/28/2024   |   Inventor(s): Juan Marugan, Susan Slaugenhuapt
Keywords(s): Derivatives, Kinetin, VEXXXX, WKXXXX, XEXXXX
Category(s): Application > Therapeutics, TherapeuticArea > Neurology
Sensor for Real-time Detection of Plasma Metabolites Levels for the Diagnosis and Care of Metabolic Disorders
This technology includes the development of devices capable of real-time evaluation of metabolite levels for the treatment of numerous metabolic disorders, including hyperammonemia and aminoacidopathies. Currently, the monitoring of metabolite levels is done in a hospital setting with specialized mass spectrometry instrumentation. As a consequence,...
Published: 10/28/2024   |   Inventor(s): Adam Behrens, Peter Kofinas, Marshell Summar, Juan Luque-Cabrera, Gary Cunningham, Juan Marugan, Anton Simeonov, Omar Ayyub
Keywords(s): Detection, DEVICE, Listed LPM Tong as of 4/15/2015, MECHANICAL, METABOLITES, Metabolites., PLASMA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REAL, SENSOR, TIME, VPXXXX, WBXXXX, WFXXXX, WIXXXX, XCXXXX, XDXXXX
Category(s): TherapeuticArea > Endocrinology, TherapeuticArea > Dental, Application > Non-Medical Devices, TherapeuticArea > Ophthalmology, Application > Consumer Products, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, TherapeuticArea > Infectious Disease, Application > Medical Devices, Application > Diagnostics, Application > Occupational Safety and Health, Application > Research Materials
Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers
This technology includes the identification and use of heterocyclic alcohol compounds, including RITA and N-BIC, for the treatment of SULT1A1-expression cancers. A high-throughput screen (qHTS) was performed using >1,000 caner cell lines identified a compound called YC-1 (also called Lificiguat) that is effective across cancer cell types that express...
Published: 10/28/2024   |   Inventor(s): Min Shen, Ke Kong, Toble Lee, Samarjit Patnaik, Olivia Lee, Jonathan Shrimp, Mindy Davis, Juan Marugan, Wei Zhao, Matthew Hall
Keywords(s): Agents, Alcohol, anti-cancer, Class, compounds, HETEROCYCLIC, SULT1A1-dependent, VCXXXX, WKXXXX, XCXXXX, XEXXXX
Category(s): Application > Research Materials, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology
Heterocyclic Compounds for the Treatment of Hepatitis C Virus
The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that have changed the HCV treatment paradigm. However, the...
Published: 10/28/2024   |   Inventor(s): Zongyi Hu, Juan Marugan, Noel Southall, Xin Hu, Jingbo Xiao, Shanshan (Melissa) He, Marc Ferrer-Alegre, Wei Zheng, Kevin Frankowski, Frank Schoenen, Kelin Li, Tsanyang (Jake) Liang
Keywords(s): C, Class, compounds, DB4BXX, Development, Hepatitis, Novel, treatment, VLXXXX, WKXXXX, YAXXXX, YBXXXX
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease
Novel Dopamine D2 Receptor Antagonists and Methods of Their Use
Investigators at the NIH have identified a series of novel, small molecule antagonists of the dopamine D2 receptor. Among the dopamine receptor (DAR) subtypes, D2 DAR is arguably one of the most validated drug targets in neurology and psychiatry. For instance, all receptor-based anti-Parkinsonian drugs work via stimulating the D2 DAR, whereas all FDA...
Published: 10/28/2024   |   Inventor(s): Juan Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Noel Southall, R Benjamin Free, David Sibley
Keywords(s): Agents, ANTAGONISTS, ANTIPSYCHOTIC, D2, Dopamine, Human, NB2BXX, NB2XXX, Potential, RECEPTOR, SELECTIVE, VEXXXX, VNXXXX, WIXXXX, WKXXXX, YBXXXX, YCXXXX
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Psychiatry/Mental Health, TherapeuticArea > Neurology, Application > Research Materials, Application > Therapeutics
1 2